Posted by SLS on August 26, 2009, at 6:51:35
In reply to Re: bifeprunox dropped, posted by jrbecker76 on August 25, 2009, at 22:52:44
> > Yeah. That does suck. It might have been a better Abilify-type drug as an adjunct medication for major depressive disorder and bipolar depression. Perhaps without the weight gain?
> >
> > Unfortunately, it seems that DA partial agonists like Abilify and bufeprunox don't make the best antipsychotics when used as monotherapy to treat schizoid disorders. They are real good as an adjunct for negative symptoms, though.
> >
> >
> > - Scott
>
> Speaking of Abilify, Otsuka is currently in trials testing a tweaked version of the Aripiprazole compound. It's most likely a metabolite or an enantiomer of the current molecule. Innovative, eh.I hope it comes to fruition. It would be great if this new drug were to spare us of the latent, insidious weight gain that Abilify produces.
As usual, thank you for providing PB with so much information and the hope that we might find wellness in the drugs that are on their way. We could use a few more D2/D3 partial agonists.
I looked at the data from some of the clinical studies of bifeprunox. Unfortunately, they were very disappointing. I really never expected it to be approved.
- Scott
poster:SLS
thread:913996
URL: http://www.dr-bob.org/babble/20090826/msgs/914136.html